Recent advances in the development of transdermal delivery systems for treatment of infertility

References

• Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
   PubMed Web of Science ®Google Scholar
• Dedakia A, Matholiya C, Koyani V, Bhimani D. Three generations: primary, secondary, and tertiary generations of transdermal drug delivery systems: a review. Int J Pharm Sci Res. 2013;4(6):2159–2173.
   Google Scholar
• Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA. 2001;285(18):2347–2354.
   PubMed Web of Science ®Google Scholar
• Venkatraman S, Gale R. Skin adhesives and skin adhesion. 1. Transdermal drug delivery systems. Biomaterials. 1998;19(13):1119–1136.
   PubMed Web of Science ®Google Scholar
• Arora A, Prausnitz MR, Mitragotri S. Micro-scale devices for transdermal drug delivery. Int J Pharm. 2008;364(2):227–236.
   PubMed Web of Science ®Google Scholar
• Cheong Y, Boomsma C, Heijnen C, Macklon N. Uterine secretomics: a window on the maternal-embryo interface. Fertil Steril. 2013;99(4):1093–1099.
   PubMed Web of Science ®Google Scholar
• Sathanandan M, Macnamee MC, Rainsbury P, Wick K, Brinsden P, Edwards RG. Replacement of frozen-thawed embryos in artificial and natural cycles: a prospective semi-randomized study. Hum Reprod. 1991;6(5):685–687.
   Web of Science ®Google Scholar
• Sher G, Herbert C, Maassarani G, Jacobs MH. Assessment of the late proliferative phase endometrium by ultrasonography in patients undergoing in-vitro fertilization and embryo transfer (IVF/ET). Hum Reprod. 1991;6(2):232–237.
   Web of Science ®Google Scholar
• Leeton J, Rogers P, Healy D. A comparison of pregnancy rates for 131 donor oocyte transfers using either a sequential or fixed regime of steroid replacement therapy. Hum Reprod. 1991;6(2):299–301.
   Web of Science ®Google Scholar
• Navot D, Anderson T, Droesch K, Scott R, Kreiner D, Rosenwaks Z. Hormonal manipulation of endometrial maturation. J Clin Endocrinol Metab. 1989;68(4):801–807.
   Web of Science ®Google Scholar
• Ryan KJ, Engel LL. The interconversion of estrone and estradiol by human tissue slices. Endocrinology. 1953;52(3):287–291.
   Web of Science ®Google Scholar
• Campbell S, Whitehead M. Potency and hepatocellular effects of oestrogens after oral, percutaneous and subcutaneous administration. In: Van Keep P, Utain W, Vermeulen A, editors. The Controversial Climacteric. Lancaster, UK: MTP Press; 1982.
   Google Scholar
• Powers M, Schenkel L, Darby PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol. 1985;152(8):1099–1106.
   Web of Science ®Google Scholar
• Rosenwaks Z. Donor eggs: their application in modern reproductive technologies. Fertil Steril. 1987;47(6):895–909.
   PubMed Web of Science ®Google Scholar
• Hancke K, More S, Kreienberg R, Jurge W. Patients undergoing frozen-thawed embryo transfer have similar live birth rates in spontaneous and artificial cycles. J Assist Reprod Genet. 2012;29(5):403–407.
   PubMed Web of Science ®Google Scholar
• Gonen Y, Casper RF, Jacobson W, Blankier J. Endometrial thickness and growth during ovarian stimulation: a possible predictor of implantation in in vitro fertilization. Fertil Steril. 1989;52(3):446–450.
   Web of Science ®Google Scholar
• Bourgain C, Devroey P, Van Waesberghe L, Smitz J, Van Seirteghem AC. Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum Reprod. 1990;5(5):537–543.
   Web of Science ®Google Scholar
• Janati S, Davar R, Mohseni F. Comparison of effect of transdermal estradiol and estradiol valerate on endometrial receptivity in frozen-thawed embryo transfer cycles. Iran J Reprod Med. 2013;11(4 Suppl):S68.
   Google Scholar
• Dal Prato L, Borini A, Cattoli M, Bonu MA, Sciajno R, Flamigni C. Endometrial preparation for frozen-thawed embryo transfer with or without pretreatment with gonadotropin-releasing hormone agonist. Fertil Steril. 2002;77(5):956–960.
   PubMed Web of Science ®Google Scholar
• Bals-Pratsch M, Al-Hasani S, Schopper B, et al. A simple, inexpensive and effective artificial cycle with exogenous transdermal oestradiol and vaginal progesterone for the transfer of cryopreserved pronucleated human oocytes in women with normal cycles. Hum Reprod. 1999; 14 Suppl 1:222–230.
   Google Scholar
• Banz C, Katalinic A, Al-Hasani S, et al. Preparation of cycles for cryopreservation transfers using estradiol patches and Crinone 8% vaginal gel is effective and does not need monitoring. Eur J Obstet Gynecol Reprod Biol. 2002;103(1):43–47.
   Web of Science ®Google Scholar
• Devroey P, Pados G. Preparation of endometrium for egg donatin. Hum Reprod Update. 1998;4(6):856–861.
   Web of Science ®Google Scholar
• Smitz J, Devroey P, Braeckmans P, et al. Management of failed cycles in an IVF/GIFT programme with the combination of a GnRH analogue and HMG. Hum Reprod. 1987;2(4):309–314.
   Web of Science ®Google Scholar
• Kolibianakis EM, Venetis CA, Papanikolaou EG, Diedrich K, Tarlatzis BC, Griesinger G. Estrogen addition to progesterone for luteal phase support in cycles stimulated with GnRH analogues and gonadorophins for IVF: a systematic review and meta-analysis. Hum Reprod. 2008;23(6):146–154.
   Web of Science ®Google Scholar
• Gelbaya TA, Kyrgiou M, Tsoumpou I, Nardo LG. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. Fertil Steril. 2008;90(6):2116–2125.
   PubMed Web of Science ®Google Scholar
• Jee BC, Suh CS, Kim SH, Kim YB, Moon SY. Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis. Fertil Steril. 2010;92(2):428–436.
   Google Scholar
• van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2011;10:CD009154.
   PubMed Web of Science ®Google Scholar
• Connell MT, Szatkowski JM, Terry N, DeCherney AH, Propst AM, Hill MJ. Timing luteal support in assisted reproductive technology: a systematic review. Fertil Steril. 2015;103(4):939–946.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Engmann L, Benadiva C. Luteal phase supplementation after gonadotropin-releasing hormone agonise trigger in fresh embryo transfer: the American versus European approaches. Fertil Steril. 2015;103(4):879–885.
   Web of Science ®Google Scholar
• Beckers NG, Macklon NS, Eijkemans MJ, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH)agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab. 2003;88(9):4186–4192.
   Web of Science ®Google Scholar
• Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89(1):84–91.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bungum L, Bungum M, et al. Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol. Reprod Biomed Online. 2005;11(6):679–684.
   PubMed Web of Science ®Google Scholar
• Dragisic K, Davis O, Fasouliotis S, Rosenwaks Z. Use of a luteal estradiol patch and a gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation for in vitro fertilization in poor responders. Fertil Steril. 2005;84(4):1023–1026.
   PubMed Web of Science ®Google Scholar
• Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod. 2003;18(12):2698–2703.
   PubMed Web of Science ®Google Scholar
• Reynolds KA, Omurtag KR, Jimenez PT, Rhee JS, Tuuli MG, Jungheim ES. Cycle cancellation and pregnancy after luteal estradiol priming in women defined as poor responders: a systematic review and meta-analysis. Hum Reprod. 2013;28(11):2981–2989.
   Web of Science ®Google Scholar
• Hill MJ, Whitcomb BW, Lewis TD, et al. Progesterone luteal support after ovulation induction and intrauterine insemination: a systematic review and meta-analysis. Fertil Steril. 2013;100(5):1373–1380.
   Web of Science ®Google Scholar
• Ryan KJ, Petro Z, Kaiser J. Steroid formation by isolated and recombined ovarian granulosa and theca cell. J Clin Endocrinol Metab. 1968;28(3):355–358.
   Web of Science ®Google Scholar
• Weil SJ, Vendola K, Zhou J, et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab. 1998;83(7):2479–2485.
   PubMed Web of Science ®Google Scholar
• Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest. 1998;101(12):2622–2629.
   PubMed Web of Science ®Google Scholar
• Vendola K, Zhou J, Wang J, Famuyiwa OA, Bievre M, Bondy CA. Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol Reprod. 1999;61(2):353–357.
   PubMed Web of Science ®Google Scholar
• Frattarelli JL, Peterson EH. Effect of androgen levels on in vitro fertilization cycles. Fertil Steril. 2004;81(6):1713–1714.
   Web of Science ®Google Scholar
• Barbieri RL, Sluss PM, Powers RD, et al. Association of body mass index, age, and cigarette smoking with serum testosterone levels in cycling women undergoing in vitro fertilization. Fertil Steril. 2005;83(2):302–308.
   Web of Science ®Google Scholar
• Haning RV Jr, Hackett RJ, Flood CA, Loughlin JS, Zhao QY, Longcope C. Plasma dehydroepiandrosterone sulfate serves as a prehormone for 48% of follicular fluid testosterone during treatment with menotropins. J Clin Endocrinol Metab. 1993;76(5):1301–1307.
   Web of Science ®Google Scholar
• Artini PG, Simi G, Ruggiero M, et al. DHEA supplementation improves follicular microenviroment in poor responder patients. Gynecol Endocrinol. 2012;28(9):669–673.
   Web of Science ®Google Scholar
• Sonmezer M, Ozmen B, Cil AP, et al. Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders. Reprod Biomed Online. 2009;19(4):508–513.
   PubMed Web of Science ®Google Scholar
• Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet. 2007;24(12):629–634.
   PubMed Web of Science ®Google Scholar
• Luo S, Li S, Li X, Qin L, Jin S. Effect of pretreatment with transdermal testosterone on poor ovarian responders undergoing IVF/ICSI: a meta-analysis. Exp Ther Med. 2014;8(1):187–194.
   Web of Science ®Google Scholar
• Zech NH, Murtinger M, Uher P. Pregnancy after ovarian superovulation by transdermal delivery of follicle-stimulating hormone. Fertil Steril. 2011;95(8):2784–2785.
   PubMed Web of Science ®Google Scholar
• NIH Small Business Innovation Research, Small Business Technology Transfer Programs. Transdermal GnRH delivery system to treat infertility. Bethesda, MD, USA: National Institutes of Health; Available from: https://www.sbir.gov/sbirsearch/detail/77730. Accessed February 16, 2015.
   Google Scholar